Author Reply: In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”

• Meridith L. Balbach, BS,
• Rosana Eisenberg, MD,
• Wade T. Iams, MD, MSCI

Affiliations

Meridith L. Balbach, BS

Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt University School of Medicine, Nashville, Tennessee

Rosana Eisenberg, MD

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee

Wade T. Iams, MD, MSCI

Address correspondence to: Wade T. Iams, MD, MSCI, Department of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232-6307.; Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee